Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Open-label, Post-approval Study of the Safety and Effectiveness of ORBERA365 As a 12-month Adjunct to Weight Reduction for Obese Adults or Pre-surgical Weight Reduction for Obese or Super-obese Adults

NCT04362774 is registered in ClinicalTrials.gov with Apollo Endosurgery, Inc. as lead sponsor.

NCT NCT04362774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04362774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Open-label, Post-approval Study of the Safety and Effectiveness of ORBERA365 As a 12-month Adjunct to Weight Reduction for Obese Adults or Pre-surgical Weight Reduction for Obese or Super-obese Adults
Lead sponsor
Apollo Endosurgery, Inc.
Phase
Observational
Overall status
Terminated
Start date
February 23, 2021
Completion date
October 10, 2023
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight